On Thursday, Shares of Apple Inc. (NASDAQ:AAPL), added 0.74% and closed at $113.89 in the last trading session. The last trading range of the stock ranges between $113.13 and $114.34. Attorneys from Dallas’ Caldwell Cassady & Curry have won another multimillion-dollar patent infringement award for Nevada-based VirnetX Holding Corp. (NYSE MKT: VHC) against technology giant Apple Inc. (AAPL) based on an East Texas jury’s finding that Apple owes more than $302 million in royalties for infringing internet security patents owned by VirnetX.
Jurors in the Tyler, Texas, courtroom of Judge Robert W. Schroeder III delivered the verdict in favor of VirnetX on Sept. 30 after one week of trial. The case is VirnetX Inc., et al. v. Apple Inc., No. 6:10-CV-417, in the U.S. District Court for the Eastern District of Texas.
Caldwell Cassady & Curry name principals Bradley W. Caldwell, Jason D. Cassady and J. Austin Curry led the team representing VirnetX. The company also called on Johnny Ward from Ward, Smith & Hill, PLLC, in Longview and attorneys from Parker, Bunt & Ainsworth, P.C., of Tyler. Also representing VirnetX from Caldwell Cassady & Curry were firm principal Justin T. Nemunaitis and firm attorneys Hamad M. Hamad, Warren J. McCarty, Jason S. McManis, Daniel R. Pearson, Christopher S. Stewart, and John F. Summers.
Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA), jumped 0.49% and closed at $45.40 in the last trading session. The last trading range of the stock ranges between $44.92 and $45.60. The company’s Market capitalization is $45.88 Billion with the total Outstanding Shares of 1.01 Billion. Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA), Celltrion, Inc. and Celltrion Healthcare recently declare that the companies have reached an exclusive partnership to commercialize two of Celltrion’s mAb biosimilar candidates in the U.S. and Canada. CT-P10 is a projected mAb biosimilar to Rituxan® (rituximab), which is used to treat patients with Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Wegener’s Granulomatosis and Microscopic Polyangiitis (MPA). CT-P6 is a projected mAb biosimilar to Herceptin® (trastuzumab), which is used for the treatment of HER2-overexpressing breast cancer and for the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Combined annual net sales for Rituxan and Herceptin are about $6.5 billion in the U.S. and Canada.
“This commercial partnership with Celltrion facilitates Teva to expand into the forthcoming wave of biosimilars and build on its strong position in the biosimilar space,” said Siggi Olafsson, President & CEO of Global Generic Medicines, Teva Pharmaceuticals. “The introduction of two additional mAb biosimilar candidates into our near-term pipeline bolsters our biosimilar portfolio and continues to leverage Teva’s unique cross-functional capabilities across both specialty and generic medicines. We look forward to our partnership with Celltrion with its expertise in mAb biosimilar development and manufacturing.”
Tahoe Resources Inc (NYSE:TAHO), lost -2.11% and closed at $11.14 in the last trading session. The last trading range of the stock ranges between $10.98 and $11.45. During the 52-week trading session the minimum price at which share price traded, registered at $4.67 and reached to max level of $17.01. Tahoe Resources Inc. (“Tahoe” or the “Company”) (TSX: THO; NYSE: TAHO) is happy to declare its tenth monthly dividend for 2016 of USD$0.02 per common share. Shareholders of record at the close of business on Thursday, October 20, 2016 will be entitled to receive payment of this dividend on Thursday, October 27, 2016.
This dividend qualifies as an “eligible dividend” for Canadian income tax purposes. Following tax legislation enacted in 2007, Canadian resident individuals who receive “eligible dividends” will be entitled to an improved gross-up and dividend tax credit on such dividends.
Tahoe reminds shareholders that they may elect to purchase additional common shares of Tahoe by reinvesting their cash dividends through Tahoe’s Dividend Reinvestment Plan (DRIP). The DRIP is right away available for enrollment by eligible shareholders and is expected to become effective for the dividend declared in October. Full details of the DRIP are offered in the plan document, “Tahoe Resources Inc. Dividend Reinvestment Plan.”